Post-earnings recap
Reported
Mon, Nov 10, 2025
EPS actual
$-1.17
EPS est.
$-1.32
EPS surprise
+11.09%
1-day move
-0.98%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that while CRISPR Therapeutics exceeded expectations on EPS, the lack of revenue data and no guidance may have contributed to the stock's slight decline. Investors may be cautious given the current market challenges highlighted by management. The stock reaction reflects uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.17 | N/A | +11.09% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about market conditions affecting growth. They reiterated their commitment to advancing their pipeline despite current challenges.
Management highlighted ongoing challenges in the market.
They emphasized the need for continued innovation and development.
No specific guidance was provided for future quarters.